Blood Journal. 24/07/2019
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine Si Lun Tam, Judith Trotman, Stephen Opat, Jan A Burger, Gavin Cull, David J Gottlieb, Rosemary Anne Harrup, Patrick Johnston, Paula Marlton, Javier Munoz, John F. Seymour, David R Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang and Andrew W. Roberts
This trial shows that zanubrutinib, a tablet taken twice daily, is very active in chronic lymphocytic leukaemia. The response rates were very high and the CLL came under good control in nearly all the patients. The good news for patients is that zanubrutinib was well tolerated with very few having to stop the tablets due to side-effects. While longer follow-up is needed, most patients remain on zanubrutinib with their CLL under very good control.